Department of Oncology, General Hospital of Northern Theater Command, No.83 Wenhua Road, Shenyang, 110840, People's Republic of China.
Department of Clinical Trial Management Agency, General Hospital of Northern Theater Command, No.83 Wenhua Road, Shenyang, 110840, People's Republic of China.
Support Care Cancer. 2021 Mar;29(3):1369-1375. doi: 10.1007/s00520-020-05621-8. Epub 2020 Jul 13.
Increasing evidence suggests that many adipokines are involved in cancer-related anorexia and cachexia syndrome (CACS), although the underlying mechanism remains to be clarify. Asprosin is a new peptide hormone mainly secreted by white adipose tissues that can increase appetite and body weight. In this cross-sectional study, we tested whether asprosin may intervene in the development of CACS.
The fasting plasma asprosin levels were determined via enzyme-linked immune-sorbent assay. Anorexia was determined using the anorexia/cachexia subscale (A/CS) of the functional assessment of anorexia/cachexia therapy (FAACT) questionnaire. The body composition was assessed using bioelectrical impedance analysis. The association of plasma asprosin with anorexia, cachexia, and nutritional status was analyzed.
One hundred twenty treatment-naïve patients with pathological confirmed gastrointestinal or lung cancer and 14 mild gastritis patients were recruited. We found no significant difference in asprosin levels between subgroups of patients by age, sex, cancer types or stage. Correlation analysis suggested that asprosin levels were positively associated with body fat mass (r = 0.248, p = 0.043). No correlations were found between asprosin levels and hemoglobin, white blood cell count, blood platelet count, albumin, C-reactive protein, glucose, cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, body mass index, body fat percentage, protein, skeletal muscle, muscle mass, lean body mass, and basal metabolic rate. Furthermore, asprosin levels were not significantly different between patients with or without cachexia. However, patients with anorexia had significantly lower asprosin levels compared with patients without anorexia. No significant difference in asprosin levels between gastritis and gastric cancer patients. Similarly, no significant change of asprosin levels occurred postoperatively in 10 gastric cancer patients.
Patients with anorexia had significantly lower asprosin levels compared with patients without anorexia. We therefore speculated that asprosin might intervene in the development of cancer anorexia and serve as a potential therapeutic target.
越来越多的证据表明，许多脂肪因子参与癌症相关厌食和恶病质综合征（CACS），但其潜在机制尚不清楚。Asprosin 是一种主要由白色脂肪组织分泌的新型肽类激素，可增加食欲和体重。在这项横断面研究中，我们测试了 asprosin 是否可能干预 CACS 的发展。
通过酶联免疫吸附试验测定空腹血浆 asprosin 水平。采用厌食/恶病质量表（A/CS）评估厌食症。使用生物电阻抗分析评估身体成分。分析血浆 asprosin 与厌食症、恶病质和营养状况的关系。
我们招募了 120 名未经治疗的病理确诊胃肠道或肺癌患者和 14 名轻度胃炎患者。我们没有发现 asprosin 水平在年龄、性别、癌症类型或分期的患者亚组之间存在显著差异。相关性分析表明，asprosin 水平与体脂肪量呈正相关（r=0.248，p=0.043）。未发现 asprosin 水平与血红蛋白、白细胞计数、血小板计数、白蛋白、C 反应蛋白、血糖、胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白、体重指数、体脂百分比、蛋白质、骨骼肌、肌肉量、瘦体重和基础代谢率之间存在相关性。此外，恶病质患者与非恶病质患者之间的 asprosin 水平无显著差异。然而，厌食症患者的 asprosin 水平明显低于无厌食症患者。胃炎和胃癌患者的 asprosin 水平无显著差异。同样，10 例胃癌患者术后 asprosin 水平无明显变化。
与无厌食症患者相比，厌食症患者的 asprosin 水平明显降低。因此，我们推测 asprosin 可能参与癌症厌食症的发展，并可能成为潜在的治疗靶点。
